Intravitreal Bevacizumab vs Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration
- 1 October 2007
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Ophthalmology (1950)
- Vol. 125 (10) , 1357-1361
- https://doi.org/10.1001/archopht.125.10.1357
Abstract
Research from JAMA Ophthalmology — Intravitreal Bevacizumab vs Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular DegenerationKeywords
This publication has 30 references indexed in Scilit:
- Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-Related Macular Degeneration with VerteporfinPublished by Oxford University Press (OUP) ,2020
- Ranibizumab versus Verteporfin for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Targeting angiogenesis, the underlying disorder in neovascular age-related macular degenerationCanadian Journal of Ophthalmology, 2005
- Pegaptanib for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2004
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNature Reviews Drug Discovery, 2004
- POTENTIAL PUBLIC HEALTH IMPACT OF AGE-RELATED EYE DISEASE STUDY RESULTS: AREDS REPORT NO. 11Evidence-Based Eye Care, 2004
- Anti-Vascular Endothelial Growth Factor Strategies for the Treatment of Choroidal Neovascularization From Age-Related Macular DegenerationInternational Ophthalmology Clinics, 2004
- Verteporfin Therapy for Subfoveal Choroidal Neovascularization in Age-Related Macular DegenerationArchives of Ophthalmology (1950), 2002
- 2′-Fluoropyrimidine RNA-based Aptamers to the 165-Amino Acid Form of Vascular Endothelial Growth Factor (VEGF165)Journal of Biological Chemistry, 1998
- Age-Related Macular Degeneration and Blindness due to Neovascular MaculopathyArchives of Ophthalmology (1950), 1984